Matches in Wikidata for { <http://www.wikidata.org/entity/Q91027071> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91027071 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q91027071 description "scientific article published on 25 October 2019" @default.
- Q91027071 description "wetenschappelijk artikel" @default.
- Q91027071 description "наукова стаття, опублікована 25 жовтня 2019" @default.
- Q91027071 name "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 name "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 type Item @default.
- Q91027071 label "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 label "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 prefLabel "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 prefLabel "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 P1433 Q91027071-4127380A-9700-4498-908E-13E120D453F7 @default.
- Q91027071 P1476 Q91027071-4C21F170-30AA-4A71-8E5E-04F277C72C20 @default.
- Q91027071 P2093 Q91027071-0B72325C-0D27-4F9E-AC5C-B6069B4581F7 @default.
- Q91027071 P2093 Q91027071-2DE51B63-7562-42FA-B20A-CFEF7F565C69 @default.
- Q91027071 P2093 Q91027071-38621404-6639-45B0-8079-C1D758076F6D @default.
- Q91027071 P2093 Q91027071-4B8BFD4D-2EBB-4B16-AA74-A5610E87675A @default.
- Q91027071 P2093 Q91027071-57016B28-B343-4944-B639-BADD17564294 @default.
- Q91027071 P2093 Q91027071-7EFF4C4B-8001-4390-ADFD-C4775B67F410 @default.
- Q91027071 P2093 Q91027071-9BDF0277-DAB5-4FA7-AE16-EFB9E38CA76E @default.
- Q91027071 P2093 Q91027071-AD2AFED9-3AA7-4698-9E87-8423F62AEC83 @default.
- Q91027071 P2093 Q91027071-C3E18F6F-7140-40B3-A7AA-C24805215F8C @default.
- Q91027071 P304 Q91027071-CF2BE35A-8E75-4EBD-B49C-390F116FEB60 @default.
- Q91027071 P31 Q91027071-8B87269D-C1ED-4F7C-BB63-0D7B1CD8C4E9 @default.
- Q91027071 P356 Q91027071-CEFD6DAA-508D-4CB2-AF31-C9A896EAE45D @default.
- Q91027071 P478 Q91027071-DD6FE7CF-B46D-442A-BC77-367820FA4F55 @default.
- Q91027071 P577 Q91027071-6EE8346A-FF9E-49B2-BA16-7CE49C6E5EFE @default.
- Q91027071 P698 Q91027071-7CE27B04-3075-4C9C-8EF9-D6EEE864A0FB @default.
- Q91027071 P356 J.EJPS.2019.105096 @default.
- Q91027071 P698 31669389 @default.
- Q91027071 P1433 Q5412738 @default.
- Q91027071 P1476 "GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles" @default.
- Q91027071 P2093 "Annelies Jorritsma-Smit" @default.
- Q91027071 P2093 "Coba J van Zanten" @default.
- Q91027071 P2093 "Daan J Touw" @default.
- Q91027071 P2093 "Derk P Allersma" @default.
- Q91027071 P2093 "Hans W Nijman" @default.
- Q91027071 P2093 "Janneke J M Meulenberg" @default.
- Q91027071 P2093 "Jolande Schoemaker" @default.
- Q91027071 P2093 "Jos G W Kosterink" @default.
- Q91027071 P2093 "Toos Daemen" @default.
- Q91027071 P304 "105096" @default.
- Q91027071 P31 Q13442814 @default.
- Q91027071 P356 "10.1016/J.EJPS.2019.105096" @default.
- Q91027071 P478 "143" @default.
- Q91027071 P577 "2019-10-25T00:00:00Z" @default.
- Q91027071 P698 "31669389" @default.